AC Immune (ACIU) Net Cash Flow (QoQ) (2016 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -146.82% |
| Sep 30, 2025 | -70.60% |
| Jun 30, 2025 | 148.67% |
| Mar 31, 2025 | -945.77% |
| Dec 31, 2024 | 109.75% |
| Sep 30, 2024 | -609.34% |
| Jun 30, 2024 | 88.15% |
| Mar 31, 2024 | -149.24% |
| Dec 31, 2023 | 675.12% |
| Sep 30, 2023 | 51.52% |
| Jun 30, 2023 | -169.33% |
| Mar 31, 2023 | 320.94% |
| Dec 31, 2022 | 35.00% |
| Sep 30, 2022 | -486.81% |
| Jun 30, 2022 | 118.89% |
| Mar 31, 2022 | -137.44% |
| Dec 31, 2021 | 3.46% |
| Sep 30, 2021 | 77.31% |
| Jun 30, 2021 | -344.27% |
| Mar 31, 2021 | 32.27% |
| Dec 31, 2020 | -2,109.77% |
| Sep 30, 2020 | 86.13% |
| Jun 30, 2020 | 47.70% |
| Mar 31, 2020 | 42.63% |
| Dec 31, 2019 | -382.80% |
| Sep 30, 2019 | 141.31% |
| Jun 30, 2019 | -124.02% |
| Mar 31, 2019 | 255.34% |
| Dec 31, 2018 | -142.76% |
| Sep 30, 2018 | 1,421.21% |
| Jun 30, 2018 | 50.83% |
| Mar 31, 2018 | -100.05% |
| Dec 31, 2017 | 197.52% |
| Sep 30, 2017 | -312,084.65% |
| Jun 30, 2017 | 19.48% |
| Mar 31, 2017 | -27.60% |
| Dec 31, 2016 | -112.47% |
| Sep 30, 2016 | 445.47% |
| Jun 30, 2016 | 272.26% |
| Mar 31, 2016 | -137.21% |